Joey Moore
Member
Brazil Human Insulin Drugs Market Overview in 2025
Market Size in 2024: USD 872.61 Million
Market Forecast in 2033: USD 1,405.02 Million
Market Growth Rate 2025-2033: 5.03%
The Brazilian human insulin drugs market is expanding steadily, underpinned by rising type-1 and type-2 diabetes prevalence, wider access through the public health system and the gradual uptake of next-generation insulin analogues. Revenue is expected to climb from USD 872.61 million in 2024 to USD 1,405.02 million by 2033, reflecting a 5.03% CAGR.
Brazil Human Insulin Drugs Market Growth Drivers
SUS Expansion of Insulin Access Reduces Out-of-Pocket Spend
In January 2025 the Ministry of Health added insulin glargine and degludec to the National Essential Medicines List, enabling 1.8 million SUS patients to receive analogues free of charge. State-level procurement data shows a 42% quarter-on-quarter jump in glargine dispensations, while patient co-payment reports fell by BRL 120 million national. The policy shift is encouraging manufacturers to submit more registrations, expanding the competitive field and sustaining volume growth across the Brazilian human insulin drugs sector.
Farmácia Popular Digital Roll-Out Boosts Adherence
The federal program migrated to a fully digital platform in March 2025, allowing patients to order insulin online and collect at 24,000 accredited private pharmacies. Within 60 days the system recorded 680,000 prescription downloads, a 28% increase over the prior paper-based process. Real-time stock visibility reduces trip cancellations, while SMS refill reminders have lifted 90-day adherence rates to 78%, directly extending therapy cycles and supporting consistent demand for Brazil human insulin drugs.
Local Biosimilar Investments Lower Import Dependence
Biomm SA inaugurated a 6,000-litre insulin biosimilar plant in Minas Gerais in April 2025, backed by BNDES financing of BRL 350 million. The facility aims to supply 30% of domestic analogue demand by 2028, cutting import exposure and shortening supply chains. With ANVISA fast-track review timelines reduced to 240 days, additional local players are filing abbreviated biosimilar applications, promising price competition that will broaden patient access and strengthen volume expansion within the Brazilian human insulin drugs market.
Request a Free Sample Copy of the Report: https://www.imarcgroup.com/brazil-human-insulin-drugs-market/requestsample
Brazil Human Insulin Drugs Market Segmentation
Product Type Insights:
- Human Insulin
- Basal Insulin
- Bolus Insulin
- Insulin Combinations
- Biosimilar Insulins
- Short Acting
- Long Acting
- Type 1 Diabetes
- Type 2 Diabetes
- Southeast
- South
- Northeast
- North
- Central-West
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Request Customization: https://www.imarcgroup.com/request?type=report&id=29015&flag=E
Brazil Human Insulin Drugs Market News:
- Mar 2025: ANVISA approves the first domestically produced insulin aspart biosimilar from Biomm, priced 35% below imported brands.
- Apr 2025: The Ministry of Health launches a national e-prescription network linking 42,000 primary-care units to reduce insulin prescription errors.
- May 2025: Novo Nordisk partners with local courier Loggi to offer same-day cold-chain delivery of insulin pens in São Paulo and Rio de Janeiro.
- Jun 2025: Federal University of Rio Grande do Sul begins Phase I trial on a once-weekly basal insulin, targeting improved adherence among adolescent type-1 patients.
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter's Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
About Us:
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, considerations studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.